Who
Joshua Resnick
Director
Company insider
Files Form 4 as: Director, PepGen; Director, Sionna Therapeutics; Director, Cidara Therapeutics; Director, Vor Biopharma; Director, Jade Biosciences; Director, KalVista Pharmaceuticals.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 21 Nov 2016
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —22,200 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,079 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —22,200 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,079 | filing |
| 18 Jun 2025filed 18 Jun 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,079 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,959 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 22 May 2025filed 23 May 2025 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 3 Jan 2025filed 7 Jan 2025 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —22,200 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 22 Jun 2023filed 26 Jun 2023 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 26 May 2023filed 2 Jun 2023 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 21 Jun 2022filed 22 Jun 2022 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.